PubMed · 1992 · 44 citations · 0 references
Life SciencesImmunologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyNatural Killer Cell BiologyNatural Killer Cell FunctionNatural Killer Cell RegulationCytotoxicity AssaysImmune Cell CytotoxicityNatural Killer Cell Activity SuppressionNatural Killer Cell CytotoxicityNatural Killer Cell Inhibitory SignalingNatural Killer Cell-based Cancer ImmunotherapyNatural Killer Cell-mediated Tumor Control
We assessed the anti-tumor activity in vivo of a kampo (Chinese) prescription Hocku-ekki-to (TJ41) in the rat and mouse tumor model. The growth of tumors was clearly inhibited in syngeneic animals given TJ-41 prophylactically. The splenic NK cells of TJ-41-treated WKA rats showed enhanced cytotoxicity against tumors including NK-sensitive YAC-1 targets. TJ-41 did not increase the splenic NK cell population, but it appeared that TJ-41 could potentiate the cytotoxic capability of each NK cell. These data indicate that TJ-41 may be useful for prophylactic immunotherapy of cancer. One of the mechanisms of the potent inhibitory effect by TJ-41 on tumor growth might be explained by its enhancement of NK activity.